Vera Therapeutics' Trutakna stabilises kidney function over two years in final Phase 3 ORIGIN 3 results
What happened? On 15 September 2026, Vera Therapeutics reported the final two-year results of its Phase 3 ORIGIN 3 trial in IgA nephropathy, a chronic autoimmune kidney disease in which antibody deposits inflame and progressively scar the kidneys' filters. Trutakna (atacicept) met all prespecified endpoints: kidney function — measured as eGFR, the rate at which the kidneys filter waste — stayed essentially flat on the drug (-0.1 after 52 weeks, an annualised decline of -0.6 through two years) versus a meaningful decline on placebo (-5.7 and -5.6). Fewer patients suffered confirmed disease progression: 11 on Trutakna versus 38 on placebo, a 76% lower risk (hazard ratio 0.24).
Why it matters: There is no cure for IgA nephropathy, which affects up to 30% of people with the condition and can lead to kidney failure and dialysis, so a therapy that stabilises kidney function rather than merely slowing its decline is a meaningful step change. Trutakna already holds US accelerated approval (granted July 2026), a conditional clearance based on proteinuria — protein leaking into urine, an early marker of kidney damage. With these final data in hand, Vera plans to file for full FDA approval in the fourth quarter of 2026, which would convert the conditional nod into a definitive one and strengthen the drug's commercial footing.
Read more: Vera Therapeutics via BioSpace, 15 September 2026 · STAT News, 15 September 2026
